Drug Trial Radar · NCT06429176
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients With Cystic Fibrosis
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
64
Planned (sponsor's estimate)
Start
Jun 24, 2024
Primary completion
Oct 1, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- SpliSense Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if drug SPL84 is safe for adult patients with cystic fibrosis (CF). It will also learn if the drug works to treat works to treat CF with a specific mutation (3849 +10kb C--\>T). The purpose of this research study is to test the safety and effectiveness of multiple doses of the study drug, SPL84. Researchers will compare drug SPL84 to a placebo (a look-alike substance that contains no drug) to see if drug SPL84 is safe and if it works to treat CF. In cohorts 1-3, SPL84 will be tested as a monotherapy, and in Cohort 4, SPL84 will be tested in participants who are already stable on CFTR modulator therapy. Participants will take drug SPL84 or a placebo by inhalation every week for 9 weeks (cohorts 1-3) or 12 weeks (cohort 4) and visit the clinic approximately weekly for checkups and tests.
Conditions
- Cystic Fibrosis
Interventions
SPL84Drug
SPL84 solution for nebulization
PlaceboOther
Placebo solution for nebulization
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability of SPL84 as evaluated by number of subjects with at least one treatment-related adverse event (AE) or serious adverse event (SAEs)Time frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)
- Safety and Tolerability of SPL84 as assessed by number of participants with abnormal heart rateTime frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)
- Safety and Tolerability of SPL84 as assessed by number of participants with abnormal respiratory rateTime frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)
- Safety and Tolerability of SPL84 as assessed by number of participants with abnormal systolic and diastolic blood pressureTime frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)
- Safety and Tolerability of SPL84 as assessed by number of participants with abnormal oximetryTime frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)
- Safety and Tolerability of SPL84 as assessed by number of participants with abnormal temperatureTime frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)
- Safety and Tolerability of SPL84 as assessed by number of participants with abnormal hematology lab test resultsTime frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)
- Safety and Tolerability of SPL84 as assessed by number of participants with abnormal biochemistry lab test resultsTime frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)
- Safety and Tolerability of SPL84 as assessed by number of participants with abnormal urinalysis lab test resultsTime frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)
- Safety and Tolerability of SPL84 as assessed by number of participants with abnormal electrocardiogram (ECG) parametersTime frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)
- Safety and Tolerability of SPL84 as assessed by number of participants with abnormal physical examination findingsTime frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)
- Safety and Tolerability of SPL84 as assessed by number of participants with abnormal pulmonary function tests resultsTime frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)
- Safety and Tolerability of SPL84 as assessed by number of participants with abnormal immunogenicity resultsTime frame: Day 1 through Day 87 (Cohort 1-3) or 108 (Cohort 4)
Locations
27 sites in 9 countries. Site status is shown where the registry gives one.
Memorial Care Long Beach Medical Center
Long Beach, California · Recruiting
University of Southern California
Los Angeles, California · Recruiting
University of California, San Francisco
San Francisco, California · Recruiting
University of California Los Angeles
Santa Monica, California · Not yet recruiting
National Jewish Health
Denver, Colorado · Recruiting
Joe DiMaggio Children's Hospital
Hollywood, Florida · Not yet recruiting
Northwestern University
Chicago, Illinois · Not yet recruiting
Boston Children'S Hospital
Boston, Massachusetts · Recruiting
University of Minnesota
Minneapolis, Minnesota · Not yet recruiting
Lenox Hill Cystic Fibrosis Center
New York, New York · Recruiting
Columbia University Cystic Fibrosis Program
New York, New York · Not yet recruiting
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina · Not yet recruiting
University of Pennsylvania
Philadelphia, Pennsylvania · Not yet recruiting
University of Utah
Salt Lake City, Utah · Not yet recruiting
Inova Fairfax Hospital
Falls Church, Virginia · Not yet recruiting
University of Washington Medical Center
Seattle, Washington · Recruiting
Motol University Hospital
Prague, Czechia · Not yet recruiting
Centre Hospitalier Régional Universitaire (CHRU) de Montpellier
Montpellier, France · Recruiting
Charité - Universitätsmedizin Berlin
Berlin, Germany · Recruiting
Klinikum Westbrandenburg CF Zentrum Potsdam
Potsdam, Germany · Recruiting
Hadassah Mt. Scopus Hospital
Jerusalem, Israel · Recruiting
Rabin Medical Center (Beilinson Hospital)
Petah Tikva, Israel · Recruiting
Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico
Milan, Italy · Recruiting
Hospital of Lithuanian University of Health Sciences Kaunas Clinics
Kaunas, Lithuania · Not yet recruiting
Kliniki Pulmonologii, Alergologii i Onkologii Pulmonologicznej Uniwersytetu Medycznego im.Karola Marcinkowskiego w Poznaniu
Poznan, Poland · Not yet recruiting
Instytut Gruźlicy i Chorób Płuc Oddział Terenowy im. Jana i Ireny Rudników
Rabka-Zdrój, Poland · Not yet recruiting
Vall d'Hebron Barcelona Hospital Campus
Barcelona, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.